Helena M A Feenstra
Overview
Explore the profile of Helena M A Feenstra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
132
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Desideri L, Anguita R, Berger L, Feenstra H, Scandella D, Sznitman R, et al.
Int J Retina Vitreous
. 2024 Jun;
10(1):42.
PMID: 38822446
Aim: To adopt a novel artificial intelligence (AI) optical coherence tomography (OCT)-based program to identify the presence of biomarkers associated with central serous chorioretinopathy (CSC) and whether these can differentiate...
2.
Feenstra H, van Dijk E, Cheung C, Ohno-Matsui K, Lai T, Koizumi H, et al.
Prog Retin Eye Res
. 2024 Feb;
101:101236.
PMID: 38301969
Central serous chorioretinopathy (CSC) is a relatively common disease that causes vision loss due to macular subretinal fluid leakage and it is often associated with reduced vision-related quality of life....
3.
Desideri L, Anguita R, Berger L, Feenstra H, Scandella D, Sznitman R, et al.
Retina
. 2023 Oct;
44(2):316-323.
PMID: 37883530
Purpose: To identify optical coherence tomography (OCT) features to predict the course of central serous chorioretinopathy (CSC) with an artificial intelligence-based program. Methods: Multicenter, observational study with a retrospective design....
4.
Pauleikhoff L, Diederen R, Feenstra H, Schlingemann R, van Dijk E, Boon C
Retina
. 2023 Jun;
43(8):1356-1363.
PMID: 37307569
Purpose: We performed a multicenter, retrospective study on patients with bilateral chronic central serous chorioretinopathy (cCSC) who received single-session bilateral reduced-settings photodynamic therapy (ssbPDT) and assessed anatomical (resolution of subretinal...
5.
Feenstra H, Diederen R, Lamme M, Tsonaka R, Fauser S, Yzer S, et al.
Retina
. 2023 Feb;
43(3):379-388.
PMID: 36727801
Purpose: A retrospective study was performed with data from the prospective randomized controlled trials, PLACE and SPECTRA, assessing the risk of foveal atrophy and the likelihood of structural and functional...
6.
Sirks M, Feenstra H, de Vries F, Dijkman G, Boon C, van Dijk E
Clin Exp Ophthalmol
. 2022 Nov;
51(2):177-179.
PMID: 36398567
No abstract available.
7.
Feenstra H, van Dijk E, van Rijssen T, Tsonaka R, Diederen R, Hoyng C, et al.
Graefes Arch Clin Exp Ophthalmol
. 2022 Oct;
261(3):659-668.
PMID: 36202933
Purpose: Comparing anatomic and functional efficacy and safety of primary treatment with either half-dose photodynamic therapy (PDT) or oral eplerenone, or crossover treatment in chronic central serous chorioretinopathy patients. Methods:...
8.
van Dijk E, Feenstra H, Bjerager J, Grauslund J, Boon C, Subhi Y
Acta Ophthalmol
. 2022 Sep;
101(2):140-159.
PMID: 36178171
Treatment of chronic central serous chorioretinopathy (cCSC) remains a topic of controversy. As cCSC is a disease that can wax and wane, treatment efficacy is difficult to assess especially when...
9.
Feenstra H, Hensman J, Gkika T, Lipkova V, Hoyng C, Diederen R, et al.
Ophthalmol Retina
. 2022 May;
6(9):861-863.
PMID: 35533974
No abstract available.
10.
Feenstra H, van Dijk E, van Rijssen T, Tsonaka R, Diederen R, Schlingemann R, et al.
Ophthalmol Retina
. 2022 Apr;
6(10):930-938.
PMID: 35470085
Purpose: To compare the efficacy and safety of crossover treatment to half-dose photodynamic therapy (PDT) and eplerenone treatment after the failure of primary treatment in patients with chronic central serous...